TickerFacts.

Nexentis Technologies Inc. (NXTS): Shareholders' Equity

Annual figures by period end, from SEC filings.

$16.01M
As of 2025-12-31
$1.91M
As of 2026-06-30
+39.9%
3-year compound annual growth
2018-12-31: $218.2K2019-12-31: -$381.1K2020-12-31: -$436.2K2021-12-31: $6.48M2022-12-31: $5.85M2023-12-31: $6.48M2024-12-31: $4.75M2025-12-31: $16.01M$16.01M
2018-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$16.01M+237.1%2026-03-31, Balance as of period end
2024-12-31$4.75M-26.7%2026-03-31, Balance as of period end
2023-12-31$6.48M+10.8%2025-03-31, Balance as of period end
2022-12-31$5.85M-9.8%2024-04-01, Balance as of period end
2021-12-31$6.48Mn/m2023-03-27, Balance as of period end
2020-12-31-$436.2Kn/m2022-03-31, Balance as of period end
2019-12-31-$381.1Kn/m2021-03-29, Balance as of period end
2018-12-31$218.2Kn/a2020-03-30, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Nexentis Technologies Inc. (NXTS)2025-12-31$16.01M+237.1%
Quoin Pharmaceuticals Ltd. (QNRX)2025-12-31$13.12M+42.5%
Evofem Biosciences, Inc. (EVFM)2025-12-31-$74.34Mn/m
Jyong Biotech Ltd. (MENS)2025-12-31-$24.91Mn/m
Abvc Biopharma, Inc. (ABVC)2025-12-31$11.11M+806.2%
Annovis Bio, Inc. (ANVS)2025-12-31$16.85M+81.0%
Galectin Therapeutics Inc (GALT)2025-12-31-$127.92Mn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31-$63.61Mn/m
Phio Pharmaceuticals Corp. (PHIO)2025-12-31$20.15M+326.6%

Compare NXTS, QNRX, EVFM, MENS side by side · Screen every company in Pharmaceutical Preparations ↗